BioSpace News Archive

CareDx, Inc. today announced a new peer-reviewed publication showing that AlloMap®, the industry’s only gene-expression profiling (GEP) blood test to non-invasively assess graft rejection by monitoring immune quiescence in heart transplant patients,1 resulted in less pain and fewer adverse events compared to heart biopsy.

Forge Biologics today announced the new availability of plasmid DNA manufacturing to its suite of scalable manufacturing services for gene therapy programs, complementing Forge’s existing AAV process development, analytical development, cGMP manufacturing, and automated final fill capabilities.

Equillium, Inc. today announced interim results from the Type B portion of the EQUALISE study evaluating itolizumab, a first-in-class anti-CD6 monoclonal antibody selectively targeting the CD6-ALCAM pathway, in patients with lupus nephritis (LN).

ZAP Surgical Systems, Inc. today announced that the Institut du Cancer Courlancy (ICC) in Reims, France will add the latest advancement in non-invasive brain tumor treatments, the ZAP-X® Gyroscopic Radiosurgery® platform, to its current portfolio of cancer treatment technologies.

Opus Genetics today announced the appointment of Adrienne Graves, Ph.D., to its board of directors.

Aktana , the leader in intelligent customer engagement for the global life sciences industry, welcomes Deepak Patil as its new senior director of medical strategy.

Eyam Vaccines and Immunotherapeutics (Eyam), has announced the acquisition of a new Option to license the patents related to an antibody biologic cancer therapeutic from the University of British Columbia (UBC).

Optellum, an Oxford-based medtech company that provides a breakthrough AI platform to diagnose and treat early-stage lung cancer, has raised $14 million in a Series A funding round.

Eagle Pharmaceuticals, Inc. and Enalare Therapeutics Inc. announced that Enalare has secured a contract for up to $50.3 million from the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response in the U.S. Department of Health and Human Services.

Cardinal Health plans to release first-quarter financial results for its fiscal year 2023 on November 4, prior to the opening of trading on the New York Stock Exchange.